Immunopathogenesis of human immunodeficiency virus: Implications for immune-based therapies

Clinical Infectious Diseases

Volumn 32, Issue 12, 2001, Pages 1738-1755

  Sereti, I ^a   Lane, H C ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CORTICOSTEROID; CYCLOSPORIN A; CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; HYDROXYUREA; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 16; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THALIDOMIDE;

ADOPTIVE IMMUNOTHERAPY; ARTICLE; COST; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; LYMPHOCYTE COUNT; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; TREATMENT OUTCOME;

ACUTE DISEASE; ANIMALS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-POSITIVE T-LYMPHOCYTES; CHRONIC DISEASE; DISEASE RESERVOIRS; HIV INFECTIONS; HIV-1; HUMANS; IMMUNE SYSTEM; IMMUNOTHERAPY; VIRUS LATENCY;

EID: 0034995684     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/320758     Document Type: Article

References (158)

1. Update on perinatal HIV transmission
2. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators
3. Acute HIV infection among patients tested for mononucleosis
4. Acute human immunodeficiency virus type 1 infection
5. Diagnosis of primary HIV infection
6. Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques
7. -T cells
8. + cell decline in HIV type 2-infected macaques
9. Control of SIV rebound through structured treatment interruptions during early infection
10. Immune control of HIV-1 after early treatment of acute infection
11. + T cell homeostasis and function in advanced HIV disease
12. Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease
13. + T cell levels: Results of 6 years of follow-up
14. Changing patterns of mortality across Europe in patients infected with HIV-1
15. Prophylaxis against opportunistic infections in patients with human immunodeficiency virus infection
16. Changes in acquired immunodeficiency syndrome-related lymphoma since the introduction of highly active antiretroviral therapy
17. + T-cell repertoire that are not immediately restored by antiviral or immune-based therapies
18. Immune reconstitution in HIV infection
19. Decay characteristics of HIV-1-infected compartments during combination therapy
20. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy
21. HIV-1 replication in patients with undetectable plasma virus receiving HAART, highly active antiretroviral therapy
22. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia
23. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy
24. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy
25. Pre-HAART HIV burden approximates post-HAART viral levels following interruption of therapy in patients with sustained viral suppression
26. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression
27. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy
28. Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression
29. Re-emergence of HIV after stopping therapy
30. Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy
31. + T cells by a highly pathogenic simian immunodeficiency virus/HIV type 1 chimera (SHIV): Implications for HIV-1 infections of humans
32. Proteasome inhibition interferes with gag polyprotein processing, release, and maturation of HIV-1 and HIV-2
33. + T cells
34. + lymphocytes
35. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA
36. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia
37. + T cells in HIV-infected progressors and long-term nonprogressors
38. HIV-1 reverse transcriptase-specific CTL against conserved epitopes do not protect against progression to AIDS
39. Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: A longitudinal analysis of rapid progressors and long-term asymptomatics
40. Longitudinal phenotypic analysis of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes: Correlation with disease progression
41. + T cells after stopping HAART is directly correlated to viral load
42. Long-term CD4 Th1 and Th2 memory following acute lymphocytic choriomeningitis virus infection
43. Viral immune evasion due to persistence of activated T cells without effector function
44. Characterization of HIV-1-specific T-helper cells in acute and chronic infection
45. + T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression
46. + T cells are maintained in untreated patients with or without proliferative responses to HIV antigens
47. + T cell proliferation and effector function in vivo
48. + T cells
49. - T cell responses associated with control of viremia
50. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy
51. Factors influencing T-cell turnover in HIV-1-seropositive patients
52. High prevalence of thymic tissue in adults with human immunodeficiency virus-1 infection
53. Changes in thymic function with age and during the treatment of HIV infection
54. + T cell turnover in HIV-infected patients
55. Rapid turnover of T lymphocytes in HIV-1 infection and its reduction by HAART: A kinetic study using deuterated glucose
56. T-cell division in human immunodeficiency virus (HIV)-1 infection is mainly due to immune activation: A longitudinal analysis in patients before and during highly active antiretroviral therapy (HAART)
57. Direct evidence for thymic function in adult humans
58. Increased cell division but not thymic dysfunction rapidly affects the T-cell receptor excision circle content of the naive T cell population in HIV-1 infection
59. 3
60. A randomized trial of high-versus low-dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type 1 infection
61. Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: A randomised controlled trial
62. Outpatient continuous intravenous interleukin-2 or subcutaneous, polyethylene glycol-modified interleukin-2 in human immunodeficiency virus-infected patients: A randomized, controlled, multicenter study
63. Subcutaneous administration of interleukin-2 in human immunodeficiency virus type 1-infected persons
64. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus
65. Community Programs for Clinical Research on AIDS. IL-2 therapy produces no change in HIV RNA after one year
66. Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy: A randomized controlled trial
67. 3: ACTG 328. Results at 60 weeks
68. Effects of intermittent interleukin-2 therapy on plasma and tissue human immunodeficiency virus levels and quasi-species expression
69. Pooled analysis of three randomized, controlled trials of interleukin-2 therapy in adult human immunodeficiency virus type 1 disease
70. Randomised study of intermittent subcutaneous interleukin-2 (IL-2) therapy without antiretrovirals versus no treatment
71. Rational interleukin 2 therapy for HIV-positive individuals: Daily low doses enhance immune function without toxicity
72. + patients: A randomized controlled trial
73. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination
74. Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys
75. Reversal of accelerated neutrophil apoptosis and restoration of respiratory burst activity with r-metHuG-CSF (Filgrastim) therapy in patients with AIDS
76. Filgrastim prevents severe neutropenia and reduces infective morbidity in patients with advanced HIV infection: Results of a randomized, multicenter, controlled trial
77. Granulocyte colony-stimulating factor use is associated with decreased bacteremia and increased survival in neutropenic HIV-infected patients
78. - T cell counts of human immunodeficiency virus - Infected patients receiving stable, highly active antiretroviral therapy: Results from a randomized, placebo-controlled trial
79. Granulocyte-macrophage colony - Stimulating factor inhibits HIV-1 replication in monocyte-derived macrophages
80. Phase III study of granulocyte-macrophage colony - Stimulating factor in advanced HIV disease: Effect on infections, CD4 cell counts and HIV suppression
81. The safety and efficacy of granulocyte-macrophage colony - Stimulating factor (Sargramostim) added to indinavir- or ritonavir-based antiretroviral therapy: A randomized double-blind, placebo-controlled trial
82. A randomized, placebo-controlled trial of granulocyte-macrophage colony-stimulating factor and nucleoside analogue therapy in AIDS
83. Anti-retroviral effects of interferon-α in AIDS-associated Kaposi's sarcoma
84. Treatment of Kaposi's sarcoma with interferon - α2b (Intron A)
85. Kaposi's sarcoma and the acquired immune deficiency syndrome: Treatment with recombinant interferon α and analysis of prognostic factors
86. Interferon-α in patients with asymptomatic human immunodeficiency virus (HIV) infection. A randomized, placebo-controlled trial
87. Efficacy and safety of combination therapy with interferon-α2b and ribavirin for chronic hepatitis C in HIV-infected patients
88. 3
89. Interleukin 10 blocks HIV replication in macrophages by inhibiting the autocrine loop of tumor necrosis factor α and interleukin 6 induction of virus
90. The inhibition of HIV replication in monocytes by interleukin 10 is linked to inhibition of cell differentiation
91. A multicenter, randomized, double-blind, placebo-controlled trial of recombinant human IL-10 in HIV-infected subjects
92. Possible role of interleukin-10 (IL-10) and CD40 ligand expression in the pathogenesis of hypergammaglobulinemia in human immunodeficiency virus infection: Modulation of IL-10 and 1g production after intravenous 1g infusion
93. Phase 1 trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: Ability to maintain IFN-γ induction is associated with clinical response
94. Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma
95. Restoration of HIV-specific cell-mediated immune responses by interleukin-12 in vitro
96. Phase 1 trial of a single dose of recombinant human interleukin-12 in human immunodeficiency virus - Infected patients with 100-500 CD4 cells/μL.
97. Therapeutic immunization of HIV-infected chimpanzees using HIV-1 plasmid antigens and interleukin-12 expressing plasmids
98. Cytokine interactions in human immunodeficiency virus - Infected individuals: Roles of interleukin (IL)-2, IL-12, and IL-15
99. IL-15 stimulates the expansion of AIDS virus - Specific CTL
100. IL-I5 enhances immune functions during HIV infection
101. IL-15 induces the expression of chemokines and their receptors in T lymphocytes
102. Cutting edge: CD4 is not required for the functional activity of IL-16
103. Role of IL-16 in HIV replication
104. Interleukin-16 (IL-16) inhibits human immunodeficiency virus replication in cells from infected subjects, and serum IL-16 levels drop with disease progression
105. Interleukin-16 inhibits human immunodeficiency virus type 1 entry and replication in macrophages and in dendritic cells
106. Interleukin 16: Implications for CD4 functions and HIV-1 progression
107. + T-cell pool
108. Interleukin-7: Physiological roles and mechanisms of action
109. Increased production of IL-7 accompanies HIV-1-mediated T-cell depletion: Implications for T-cell homeostasis
110. A potential role for IL-7 in T-cell homeostasis in HIV-infected patients
111. Hydroxyurea as an inhibitor of human immunodeficiency virus - Type 1 replication
112. Combination of a drug targeting the cell with a drug targeting the virus controls human immunodeficiency virus type 1 resistance
113. Long-term suppression of HIV-1 by hydroxyurea and didanosine
114. Treatment of human immunodeficiency virus infection with hydroxyurea, didanosine, and a protease inhibitor before seroconversion is associated with normalized immune parameters and limited viral reservoir
115. Didanosine plus stavudine with or without hydroxyurea in HIV-1-infected patients: 1 year follow-up
116. A randomized study of the safety, and antiretroviral activity of hydroxyurea combined with didanosine in persons infected with human immunodeficiency virus type 1
117. Randomized trial of continued indinavir (IDV) versus switch to IDV/ddI/d4T or IDV/ddI/d4T + hydroxyurea in patients with viral suppression
118. Incidence of pancreatitis in HIV-infected patients receiving nucleoside reverse transcriptase inhibitor drugs
119. A controlled trial of early adjunctive treatment with corticosteroids for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome
120. + T lymphocytes from activation-induced apoptosis triggered by HIV-1: Implications for pathogenesis and therapy
121. Sustained increases in CD4 cell counts in asymptomatic human immunodeficiency virus type 1 - Seropositive patients treated with prednisolone for 1 year
122. Effects of tapering doses of oral prednisone on viral load among HIV-infected patients with unexplained weight loss
123. High prevalence of avascular necrosis (AVN) of the hip in HIV infection: Magnetic resonance of 339 asymptomatic patients
124. Inflammatory reactions in HIV-1-infected persons after initiation of highly active antiretroviral therapy
125. Inhibition of HIV-1 replication by cyclosporine A or related compounds correlates with the ability to disrupt the Gagcyclophilin A interaction
126. Specific incorporation of cyclophilin A into HIV-1 virions
127. Long-term follow-up of HIV positive asymptomatic patients having received cyclosporin A
128. Cyclosporin A modulation of early virologic and immunologic events during primary simian immunodeficiency virus infection in rhesus monkeys
129. Cyclosporin A in combination with HAART in primary HIV-1 infection
130. Effects of mycophenolic acid on human immunodeficiency virus infection in vitro and in vivo
131. Thalidomide inhibits the replication of human immunodeficiency virus type 1
132. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection
133. Thalidomide for the treatment of AIDS-associated wasting
134. Prospects for the control of AIDS by immunizing seropositive individuals
135. Is an HIV vaccine possible?
136. Double-blinded, randomized, comparative trials of 4 human immunodeficiency virus type 1 (HIV-1) envelope vaccines in HIV-1-infected individuals across a spectrum of disease severity: AIDS Clinical Trials Groups 209 and 214
137. Efficacy testing of recombinant human immunodeficiency virus (HIV) gp160 as a therapeutic vaccine in early-stage HIV-1-infected volunteers, rgp160 Phase II Vaccine Investigators
138. Recombinant gp160 as a therapeutic vaccine for HIV infection: Results of a large randomized, controlled trial
139. Therapeutic immunisation with recombinant gp160 in HIV-1 infection: A randomised double-blind placebo-controlled trial
140. Active immunization of patients with HIV infection: A study of the effect of VaxSyn, a recombinant HIV envelope subunit vaccine, on progression of immunodeficiency
141. Phase II controlled trial of post-exposure immunization with recombinant gp160 versus antiretroviral therapy in asymptomatic HIV-1-infected adults
142. - T cell memory in subjects with chronic HIV type 1 infection receiving an HIV type 1 immunogen
143. HIV-1-specific CD4 helper function in persons with chronic HIV-1 infection on antiviral drug therapy, as measured by ELISPOT after treatment with an inactivated, gp120-depleted HIV-1 in incomplete Freund's adjuvant
144. Evaluation of HIV-1 immunogen, an immunologic modifier, administered to patients infected with HIV having 300 to 549 × 106/L CD4 cell counts: A randomized controlled trial
145. T-helper-cell proliferative responses to whole-killed human immunodeficiency virus type 1 (HIV-1) and p24 antigens of different clades in HIV-1-infected subjects vaccinated with HIV-1 immunogen (Remune)
146. In vitro p24 antigen - Stimulated lymphocyte proliferation and β-chemokine production in human immunodeficiency virus type 1 (HIV-1)-seropositive subjects after immunization with an inactivated gp120-depleted HIV-1 immunogen (Remune)
147. Randomised trial of MNrgp120 HIV-1 vaccine in symptomless HIV-1 infection
148. Therapeutic vaccination with p24-VLP and zidovudine augments H1V-specific cytotoxic T lymphocyte activity in asymptomatic HIV-infected individuals
149. Deficient cellular immunity: Finding and fixing the defects
150. T-cell therapy of cytomegalovirus and human immunodeficiency virus infection
151. Ex vivo expansion of HIV type 1 - Specific cytolytic T cells from HIV type 1 - Seropositive subjects
152. + T cells in human immunodeficiency virus - Infected subjects
153. Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection
154. HIV-specific cytotoxic T lymphocytes traffic to lymph nodes and localize at sites of HIV replication and cell death
155. + CTL clones is limited by elimination due to encounter with HIV-infected targets
156. Rapid death of adoptively transferred T cells in acquired immunodeficiency syndrome
157. Transfer of HIV-1 - Specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression